Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia–a study of the Acute Leukemia Working Party of the EBMT

Thomas Heinicke*, Myriam Labopin, Emmanuelle Polge, Matthias Stelljes, Arnold Ganser, Johanna Tischer, Arne Brecht, Nicolaus Kröger, Dietrich W. Beelen, Christof Scheid, Wolfgang Bethge, Peter Dreger, Donald Bunjes, Eva Wagner, Uwe Platzbecker, Bipin N. Savani, Arnon Nagler, Mohamad Mohty

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients <55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients ≥55 years LFS was best with FLAMSA-Chemo without significant differences compared to FLAMSA-TBI4 and Mel-Flu-TBI8. Furthermore, best NRM rates were obtained with the two FLAMSA regimens groups. Our study suggests that in younger (<55 years) patients a more intense regimen might be used whereas in older (≥55 years) patients the focus might be more on tolerability.

Original languageEnglish
Pages (from-to)399-409
Number of pages11
JournalLeukemia and Lymphoma
Volume62
Issue number2
DOIs
StatePublished - 2021

Keywords

  • Relapsed/refractory AML
  • clinical results
  • sequential conditioning regimens

Fingerprint

Dive into the research topics of 'Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia–a study of the Acute Leukemia Working Party of the EBMT'. Together they form a unique fingerprint.

Cite this